Details for Patent: 10,239,846
✉ Email this page to a colleague
Which drugs does patent 10,239,846 protect, and when does it expire?
Patent 10,239,846 protects ZEPOSIA and is included in one NDA.
This patent has one hundred and eleven patent family members in thirty-one countries.
Summary for Patent: 10,239,846
Title: | Selective sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
Abstract: | Compounds that selectively modulate the sphingosine 1 phosphate receptor are provided including compounds which modulate subtype 1 of the S1P receptor. Methods of chiral synthesis of such compounds are provided. Uses, methods of treatment or prevention and methods of preparing inventive compositions including inventive compounds are provided in connection with the treatment or prevention of diseases, malconditions, and disorders for which modulation of the sphingosine 1 phosphate receptor is medically indicated. |
Inventor(s): | Martinborough; Esther (San Diego, CA), Boehm; Marcus F. (San Diego, CA), Yeager; Adam Richard (La Mesa, CA), Tamiya; Junko (Carlsbad, CA), Huang; Liming (San Diego, CA), Brahmachary; Enugurthi (San Diego, CA), Moorjani; Manisha (San Diego, CA), Timony; Gregg Alan (San Diego, CA), Brooks; Jennifer L. (Encinitas, CA), Peach; Robert (San Diego, CA), Scott; Fiona Lorraine (San Diego, CA), Hanson; Michael Allen (San Marcos, CA) |
Assignee: | CELGENE INTERNATIONAL II S RL (Couvet, CH) |
Application Number: | 15/406,128 |
Patent Claim Types: see list of patent claims | Use; |
Patent landscape, scope, and claims: | More… ↓ |
Drugs Protected by US Patent 10,239,846
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS | ⤷ Subscribe | ||||
Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-002 | Mar 25, 2020 | RX | Yes | No | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS | ⤷ Subscribe | ||||
Bristol | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,239,846
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
European Patent Office | 2498610 | ⤷ Subscribe | 301076 | Netherlands | ⤷ Subscribe |
European Patent Office | 2498610 | ⤷ Subscribe | 132020000000147 | Italy | ⤷ Subscribe |
European Patent Office | 2498610 | ⤷ Subscribe | LUC00184 | Luxembourg | ⤷ Subscribe |
European Patent Office | 2498610 | ⤷ Subscribe | PA2020533 | Lithuania | ⤷ Subscribe |
European Patent Office | 2498610 | ⤷ Subscribe | CA 2020 00053 | Denmark | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |